No Data
No Data
NewAmsterdam Pharma(NAMS.US) 10% Shareholder Sells US$4.07 Million in Common Stock
$NewAmsterdam Pharma(NAMS.US)$ 10% Shareholder ForGrowth NAP B.V. sold 157.23K shares of common stock on Dec 18, 19, 2024 at an average price of $25.8641 for a total value of $4.07 million. This
Positive Outlook for NewAmsterdam Pharma Driven by Strong Financial Position and Promising Obicetrapib Trial Results
NewAmsterdam Pharma(NAMS.US) 10% Shareholder Sells US$4.86 Million in Common Stock
$NewAmsterdam Pharma(NAMS.US)$ 10% Shareholder ForGrowth NAP B.V. sold 191.76K shares of common stock on Dec 12, 13, 2024 at an average price of $25.3433 for a total value of $4.86 million. This
Menarini Group Announces Positive Topline Data From Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib With Ezetimibe 10 Mg
Walgreens Boots Alliance, Alaska Air And RH Are Among Top Mid-Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio?
Press Release: NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares